Lestaurtinib

N/A

Report date: 2022/10/14 20:00:43
NME

Base Information

Drug NameLestaurtinib
Drug Alias Name来妥替尼Lestaurtinibum来他替尼A-154475.0SPM-924 +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNerve growth factor receptor Trk-A antagonistsNeurotrophic tyrosine kinase receptor type 2 inhibitorsTyrosine-protein kinase JAK2 inhibitors +[5] 
TargetsTyrosine-protein kinase JAK2Neurotrophic tyrosine kinase receptor type 3Nerve growth factor receptor Trk-A +[5] 
Therapy Area/IndicationsPsoriasisPrimary MyelofibrosisThrombocythemia, Essential +[12] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesUkraine +[13] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesKyowa Hakko Kirin Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer Institute
Inactive CompaniesThe University Of Texas MD Anderson Cancer CenterCephalon
Active IndicationsPrecursor T-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia
Inactive IndicationsPsoriasisPrimary MyelofibrosisThrombocythemia, Essential +[9] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG